BioCentury on BioBusiness,
Table: EPS watch
Back to the parent article
Monday, January 27, 2014
At least seven biotechs and pharmas reported earnings
last week. Big pharmas Bristol-Myers Squibb (NYSE:BMY) and Johnson
& Johnson (NYSE:JNJ) lost a combined $18.2 billion in market
value last week despite beating consensus EPS and revenue estimates. ISI Group's
Mark Schoenebaum noted that BMS "seemed a bit cautious on the combination
of its PD-1 and Yervoy in lung cancer" on the earnings call. BMS's
nivolumab mAb against programmed cell death 1 (PDCD1; PD-1; CD279) and Yervoy
ipilimumab are in the Phase I CheckMate 012 trial to treat non-small cell lung
cancer (NSCLC). BMS ended the week down 6%. J&J, which fell 5%, provided
2014 EPS guidance below the Street's expectations.
Forest Laboratories Inc. (NYSE:FRX) reached its
52-week high of $72.40 on the day it announced EPS and revenues that beat the
Street. The pharma was off 6% on the week.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]